Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan

Exclusion Criteria

• •Renal damage caused by other causes;
• •Uncontrolled hypertension (blood pressure constantly greater than 140/ 90mmHg);
• •Type 1 Diabetes
• •Any acute and chronic infections;
• •Glycosylated hemoglobin (HbA1c)\>7.5%;
• •24h urinary protein quantity\>3g, serum albumin\<25g /L and estimated glomerular filtration rate (eGFR)\<60 ml/min;
• •Patients who suffered from malignant tumors or any illness that endanger life, such as liver, kidney, heart and lung function insufficiency over the past 5 years;
• •People who have received the gastrointestinal operation, which may affect absorption of Vitamin D;
• •People who have taken such drugs as angiotensin receptor blocker, calcium, and angiotensin converting enzyme inhibitor that affect excretion of urine protein, and who have been allergic to Vitamin D;
• •Pregnant or lactating women;
• •Other candidates that are deemed not suitable by investigators.